ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

Arcutis Announces Appointment of Neha Krishnamohan to Board of Directors

02 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

Arcutis to Present at Upcoming Investor Conference

01 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-2 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

23 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Announces Arcutis Cares™ Patient Assistance Program (PAP) For Financially Qualified Uninsured and Underinsured Patients

22 Aug 2022 07:00:00 By Nasdaq GlobeNewswire

Arcutis Launches ZORYVE™ (Roflumilast) Cream 0.3% in the United States for Treatment of Plaque Psoriasis in Individuals Age 12 and Older

10 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Arcutis Announces Second Quarter 2022 Financial Results and Provides Business Update

04 Aug 2022 15:01:00 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis

04 Aug 2022 07:00:02 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Aug 2022 16:55:54 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Pricing of Public Offering of Common Stock

02 Aug 2022 20:26:57 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Proposed Public Offering of Common Stock

02 Aug 2022 15:02:00 By Nasdaq GlobeNewswire

FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older

29 Jul 2022 15:05:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Announces Health Canada Accepts for Review the New Drug Submission for Roflumilast Cream for Adults and Adolescents with Plaque Psoriasis

11 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 Jul 2022 15:04:00 By Nasdaq GlobeNewswire

Arcutis Announces Positive Topline Results from STRATUM Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Seborrheic Dermatitis

06 Jun 2022 06:30:00 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 Jun 2022 15:16:00 By Nasdaq GlobeNewswire

CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 May 2022 09:33:12 By Nasdaq GlobeNewswire

Nationwide Survey of People with Seborrehic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care

25 May 2022 07:00:01 By Nasdaq GlobeNewswire

Arcutis Announces First Quarter 2022 Financial Results and Provides Business Update

05 May 2022 15:01:01 By Nasdaq GlobeNewswire

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2022 07:00:04 By Nasdaq GlobeNewswire

Arcutis Completes Enrollment in ARRECTOR Pivotal Phase 3 Trial of Topical Roflumilast Foam in Scalp and Body Psoriasis

06 Apr 2022 07:00:01 By Nasdaq GlobeNewswire